Eli Lilly Introduces Online Access to Obesity Care and Delivery Services

Eli Lilly Introduces Online Access to Obesity Care and Delivery Services

Eli Lilly & Co. has introduced LillyDirect, a new online platform aimed at enhancing access to healthcare for individuals with obesity, migraine, and diabetes. This initiative provides patients with a more direct path to obtain prescriptions for weight loss drugs, such as the company's recently approved Zepbound, through telehealth providers. Despite the innovative service, LillyDirect does not offer discounts on its medications, which could be a barrier for many patients due to the high cost of these drugs. The service is specifically designed for patients with a body mass index (BMI) of 30 or more, or at least 27 with additional weight-related health conditions.

The digital platform also offers disease management resources, home delivery of certain medications through third-party pharmacy services, and a digital pharmacy that facilitates online fulfillment. For those who qualify, savings card discounts are automatically applied, and medications are shipped without additional charges. Additionally, LillyDirect provides an independent search tool for patients who prefer to find healthcare professionals for in-person care. Eli Lilly emphasizes that the drugs are intended for approved uses and has taken legal action against entities allegedly selling products with tirzepatide, an active ingredient in its medications, for non-approved or cosmetic purposes. Looking ahead, the company plans to expand LillyDirect with new products and services to support medication adherence.

Summary

Other news in health